PubMed:32513289 / 674-1153
Annnotations
LitCovid-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T9 | 28-38 | CHEBI:31705 | denotes | ivermectin |
| T10 | 28-38 | CHEBI:31705 | denotes | ivermectin |
| T11 | 53-63 | SP_7 | denotes | SARS-CoV-2 |
| T12 | 64-69 | NCBITaxon:10239 | denotes | viral |
| T13 | 82-96 | UBERON:0001728 | denotes | nasopharyngeal |
| T14 | 318-328 | CHEBI:31705 | denotes | ivermectin |
| T15 | 318-328 | CHEBI:31705 | denotes | ivermectin |
| T16 | 382-388 | UBERON:0002405 | denotes | immune |
| T17 | 382-397 | GO:0006955 | denotes | immune response |
| T18 | 406-416 | SP_7 | denotes | SARS-CoV-2 |
| T19 | 468-478 | SP_7 | denotes | SARS-CoV-2 |
Inflammaging
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T6 | 0-479 | Sentence | denotes | 1.To assess the efficacy of ivermectin to reduce the SARS-CoV-2 viral load in the nasopharyngeal swab at day 7 post treatment.2.To assess the efficacy of ivermectin to improve symptom progression in treated patients.3.To assess the proportion of seroconversions in treated patients at day 21.4.To assess the safety of ivermectin at the proposed dose.5.To determine the magnitude of immune response against SARS-CoV-2.6.To assess the early kinetics of immunity against SARS-CoV-2. |
| T6 | 0-479 | Sentence | denotes | 1.To assess the efficacy of ivermectin to reduce the SARS-CoV-2 viral load in the nasopharyngeal swab at day 7 post treatment.2.To assess the efficacy of ivermectin to improve symptom progression in treated patients.3.To assess the proportion of seroconversions in treated patients at day 21.4.To assess the safety of ivermectin at the proposed dose.5.To determine the magnitude of immune response against SARS-CoV-2.6.To assess the early kinetics of immunity against SARS-CoV-2. |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T6 | 53-61 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T7 | 406-414 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T8 | 468-476 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T2 | 28-38 | Chemical | denotes | ivermectin | http://purl.obolibrary.org/obo/CHEBI_6078 |
| T3 | 154-164 | Chemical | denotes | ivermectin | http://purl.obolibrary.org/obo/CHEBI_6078 |
| T4 | 318-328 | Chemical | denotes | ivermectin | http://purl.obolibrary.org/obo/CHEBI_6078 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 382-397 | http://purl.obolibrary.org/obo/GO_0006955 | denotes | immune response |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T6 | 0-479 | Sentence | denotes | 1.To assess the efficacy of ivermectin to reduce the SARS-CoV-2 viral load in the nasopharyngeal swab at day 7 post treatment.2.To assess the efficacy of ivermectin to improve symptom progression in treated patients.3.To assess the proportion of seroconversions in treated patients at day 21.4.To assess the safety of ivermectin at the proposed dose.5.To determine the magnitude of immune response against SARS-CoV-2.6.To assess the early kinetics of immunity against SARS-CoV-2. |